Myeloid growth factors: Clinical practice guidelines in oncology™

Jeffrey Crawford; Betsy Althaus; James Armitage; Lodovico Balducci; Charles Bennett; Douglas W. Blayney; Spero R. Cataland; David C. Dale; George D. Demetri; Harry P. Erba; James Foran; Alison G. Freifeld; Mark L. Heaney; Sally Htoy; Dwight D. Kloth; Gary H. Lyman; Wells A. Messersmith; Laura Boehnke Michaud; Sarah C. Miyata; Amy Robbins; Martin S. Tallman; Saroj Vadhan-Raj; Peter Westervelt; Michael K. Wong

doi:10.6004/jnccn.2007.0019

Myeloid growth factors: Clinical practice guidelines in oncology™

Jeffrey Crawford, Betsy Althaus, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Mark L. Heaney, Sally Htoy, Dwight D. Kloth, Gary H. Lyman, Wells A. Messersmith, Laura Boehnke Michaud, Sarah C. Miyata, Amy RobbinsMartin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt, Michael K. Wong

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Chemotherapy-induced neutropenia can cause complications that result in dose reductions or treatment delays that can, in turn, compromise clinical outcomes. Although the prophylactic use of colony-stimulating factors (CSFs) can reduce the risk, severity, and duration of severe and febrile neutropenia, they are not routinely administered to all patients undergoing myelosuppressive chemotherapy because of the costs. Selective use may, however, enhance their cost-effectiveness. These guidelines discuss the preventative or prophylactic use of recombinant human granulocyte-CSF to reduce the incidence, length, and severity of chemotherapy-related neutropenia and and prevent life-threatening complications.

Original language	English
Pages (from-to)	188-202
Number of pages	15
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	5
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2007.0019
State	Published - Feb 2007

Keywords

Chemotherapy
Fever
Myeloid growth factors
NCCN Clinical Practice Guidelines
Neutropenia

Access to Document

10.6004/jnccn.2007.0019

Cite this

Crawford, J., Althaus, B., Armitage, J., Balducci, L., Bennett, C., Blayney, D. W., Cataland, S. R., Dale, D. C., Demetri, G. D., Erba, H. P., Foran, J., Freifeld, A. G., Heaney, M. L., Htoy, S., Kloth, D. D., Lyman, G. H., Messersmith, W. A., Michaud, L. B., Miyata, S. C., ... Wong, M. K. (2007). Myeloid growth factors: Clinical practice guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 5(2), 188-202. https://doi.org/10.6004/jnccn.2007.0019

@article{8a62ceb26ae64e5bb434f465edcb1b5b,

title = "Myeloid growth factors: Clinical practice guidelines in oncology{\texttrademark}",

abstract = "Chemotherapy-induced neutropenia can cause complications that result in dose reductions or treatment delays that can, in turn, compromise clinical outcomes. Although the prophylactic use of colony-stimulating factors (CSFs) can reduce the risk, severity, and duration of severe and febrile neutropenia, they are not routinely administered to all patients undergoing myelosuppressive chemotherapy because of the costs. Selective use may, however, enhance their cost-effectiveness. These guidelines discuss the preventative or prophylactic use of recombinant human granulocyte-CSF to reduce the incidence, length, and severity of chemotherapy-related neutropenia and and prevent life-threatening complications.",

keywords = "Chemotherapy, Fever, Myeloid growth factors, NCCN Clinical Practice Guidelines, Neutropenia",

author = "Jeffrey Crawford and Betsy Althaus and James Armitage and Lodovico Balducci and Charles Bennett and Blayney, {Douglas W.} and Cataland, {Spero R.} and Dale, {David C.} and Demetri, {George D.} and Erba, {Harry P.} and James Foran and Freifeld, {Alison G.} and Heaney, {Mark L.} and Sally Htoy and Kloth, {Dwight D.} and Lyman, {Gary H.} and Messersmith, {Wells A.} and Michaud, {Laura Boehnke} and Miyata, {Sarah C.} and Amy Robbins and Tallman, {Martin S.} and Saroj Vadhan-Raj and Peter Westervelt and Wong, {Michael K.}",

year = "2007",

month = feb,

doi = "10.6004/jnccn.2007.0019",

language = "English",

volume = "5",

pages = "188--202",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "2",

}

Crawford, J, Althaus, B, Armitage, J, Balducci, L, Bennett, C, Blayney, DW, Cataland, SR, Dale, DC, Demetri, GD, Erba, HP, Foran, J, Freifeld, AG, Heaney, ML, Htoy, S, Kloth, DD, Lyman, GH, Messersmith, WA, Michaud, LB, Miyata, SC, Robbins, A, Tallman, MS, Vadhan-Raj, S, Westervelt, P & Wong, MK 2007, 'Myeloid growth factors: Clinical practice guidelines in oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 5, no. 2, pp. 188-202. https://doi.org/10.6004/jnccn.2007.0019

TY - JOUR

T1 - Myeloid growth factors

T2 - Clinical practice guidelines in oncology™

AU - Crawford, Jeffrey

AU - Althaus, Betsy

AU - Armitage, James

AU - Balducci, Lodovico

AU - Bennett, Charles

AU - Blayney, Douglas W.

AU - Cataland, Spero R.

AU - Dale, David C.

AU - Demetri, George D.

AU - Erba, Harry P.

AU - Foran, James

AU - Freifeld, Alison G.

AU - Heaney, Mark L.

AU - Htoy, Sally

AU - Kloth, Dwight D.

AU - Lyman, Gary H.

AU - Messersmith, Wells A.

AU - Michaud, Laura Boehnke

AU - Miyata, Sarah C.

AU - Robbins, Amy

AU - Tallman, Martin S.

AU - Vadhan-Raj, Saroj

AU - Westervelt, Peter

AU - Wong, Michael K.

PY - 2007/2

Y1 - 2007/2

N2 - Chemotherapy-induced neutropenia can cause complications that result in dose reductions or treatment delays that can, in turn, compromise clinical outcomes. Although the prophylactic use of colony-stimulating factors (CSFs) can reduce the risk, severity, and duration of severe and febrile neutropenia, they are not routinely administered to all patients undergoing myelosuppressive chemotherapy because of the costs. Selective use may, however, enhance their cost-effectiveness. These guidelines discuss the preventative or prophylactic use of recombinant human granulocyte-CSF to reduce the incidence, length, and severity of chemotherapy-related neutropenia and and prevent life-threatening complications.

AB - Chemotherapy-induced neutropenia can cause complications that result in dose reductions or treatment delays that can, in turn, compromise clinical outcomes. Although the prophylactic use of colony-stimulating factors (CSFs) can reduce the risk, severity, and duration of severe and febrile neutropenia, they are not routinely administered to all patients undergoing myelosuppressive chemotherapy because of the costs. Selective use may, however, enhance their cost-effectiveness. These guidelines discuss the preventative or prophylactic use of recombinant human granulocyte-CSF to reduce the incidence, length, and severity of chemotherapy-related neutropenia and and prevent life-threatening complications.

KW - Chemotherapy

KW - Fever

KW - Myeloid growth factors

KW - NCCN Clinical Practice Guidelines

KW - Neutropenia

UR - http://www.scopus.com/inward/record.url?scp=33947213304&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2007.0019

DO - 10.6004/jnccn.2007.0019

M3 - Article

C2 - 17335688

AN - SCOPUS:33947213304

SN - 1540-1405

VL - 5

SP - 188

EP - 202

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 2

ER -

Myeloid growth factors: Clinical practice guidelines in oncology™

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this